AR122899A1 - Combinación de vacunas - Google Patents
Combinación de vacunasInfo
- Publication number
- AR122899A1 AR122899A1 ARP210101904A ARP210101904A AR122899A1 AR 122899 A1 AR122899 A1 AR 122899A1 AR P210101904 A ARP210101904 A AR P210101904A AR P210101904 A ARP210101904 A AR P210101904A AR 122899 A1 AR122899 A1 AR 122899A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccines
- cov
- sars
- antigens
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a vacunas combinadas tanto contra la influenza como contra la COVID-19. En particular, la invención se refiere a vacunas combinadas que comprenden uno o más antígenos del virus de la influenza y uno o más antígenos del SARS-CoV-2 (coronavirus SARS-CoV-2), particularmente uno o más antígenos de la proteína espiga del SARS-CoV-2, así como vacunas que comprenden polinucleótidos que codifican dichos antígenos, y tales vacunas para el tratamiento o la prevención de la COVID-19 (infección por SARS-CoV-2) e infección por influenza.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2010425.3A GB2596820A (en) | 2020-07-07 | 2020-07-07 | Combination vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122899A1 true AR122899A1 (es) | 2022-10-12 |
Family
ID=72050416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101904A AR122899A1 (es) | 2020-07-07 | 2021-07-07 | Combinación de vacunas |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230256085A1 (es) |
EP (1) | EP4178612A1 (es) |
JP (1) | JP2023533772A (es) |
KR (1) | KR20230049084A (es) |
CN (1) | CN117957016A (es) |
AR (1) | AR122899A1 (es) |
AU (1) | AU2021303789A1 (es) |
BR (1) | BR112023000323A2 (es) |
CA (1) | CA3184878A1 (es) |
CO (1) | CO2023001072A2 (es) |
GB (1) | GB2596820A (es) |
IL (1) | IL299735A (es) |
MX (1) | MX2023000411A (es) |
TW (1) | TW202207979A (es) |
WO (1) | WO2022009121A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
CN113521269A (zh) | 2020-04-22 | 2021-10-22 | 生物技术Rna制药有限公司 | 冠状病毒疫苗 |
CN113980140B (zh) * | 2020-10-23 | 2024-06-25 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 融合蛋白及其应用 |
CN113293145B (zh) * | 2021-02-01 | 2022-08-26 | 上海青赛生物科技有限公司 | 一种麻疹病毒活载体新冠疫苗 |
US20240226277A1 (en) * | 2021-04-14 | 2024-07-11 | ModernaTX. Inc. | Influenza-coronavirus combination vaccines |
CN113462700B (zh) * | 2021-05-07 | 2023-06-09 | 杨光华 | SARS-CoV-2线性DNA疫苗 |
CN114717251B (zh) * | 2021-08-24 | 2023-03-24 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2原始株和Beta株的腺病毒载体疫苗 |
WO2023047419A1 (en) * | 2021-09-24 | 2023-03-30 | Bharat Biotech International Limited | A vaccine for coronavirus and influenza virus, and method for preparation thereof |
CN113755644B (zh) * | 2021-09-24 | 2024-05-03 | 中国科学院武汉病毒研究所 | 一种检测新型冠状病毒Alpha和Delta突变体试剂盒及应用 |
CN114891817A (zh) * | 2022-04-15 | 2022-08-12 | 华南理工大学 | 一种多聚肽及其制备方法与应用 |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
CN115992101B (zh) * | 2023-03-22 | 2023-07-28 | 深圳市卫光生物制品股份有限公司 | 一种流感病毒裂解疫苗原液的制备方法 |
CN116350769B (zh) * | 2023-03-31 | 2024-07-19 | 北京吉诺卫生物科技有限公司 | 一种新冠病毒和流感病毒的联合疫苗、其制备方法与应用 |
CN116327910B (zh) * | 2023-03-31 | 2024-05-03 | 北京吉诺卫生物科技有限公司 | 一种新冠病毒、流感病毒和/或rsv的联合疫苗、其制备方法与应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
CN1775287A (zh) * | 2004-11-16 | 2006-05-24 | 北京科兴生物制品有限公司 | 一种sars流感二价联合疫苗及其制备工艺 |
GB0822001D0 (en) * | 2008-12-02 | 2009-01-07 | Glaxosmithkline Biolog Sa | Vaccine |
GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
US20130236494A1 (en) * | 2012-03-06 | 2013-09-12 | Crucell Holland B.V. | Vaccination against influenza |
CN107961371B (zh) * | 2017-04-19 | 2020-08-11 | 武汉博沃生物科技有限公司 | 季节流感-rsv联合疫苗及其制备方法和应用 |
CN110974950B (zh) * | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
CN111217917B (zh) * | 2020-02-26 | 2020-10-23 | 康希诺生物股份公司 | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 |
CN111218458B (zh) * | 2020-02-27 | 2020-11-20 | 珠海丽凡达生物技术有限公司 | 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法 |
-
2020
- 2020-07-07 GB GB2010425.3A patent/GB2596820A/en not_active Withdrawn
-
2021
- 2021-07-07 US US18/015,025 patent/US20230256085A1/en active Pending
- 2021-07-07 AU AU2021303789A patent/AU2021303789A1/en active Pending
- 2021-07-07 KR KR1020237003756A patent/KR20230049084A/ko unknown
- 2021-07-07 IL IL299735A patent/IL299735A/en unknown
- 2021-07-07 JP JP2023501632A patent/JP2023533772A/ja active Pending
- 2021-07-07 MX MX2023000411A patent/MX2023000411A/es unknown
- 2021-07-07 CA CA3184878A patent/CA3184878A1/en active Pending
- 2021-07-07 CN CN202180054553.3A patent/CN117957016A/zh active Pending
- 2021-07-07 WO PCT/IB2021/056102 patent/WO2022009121A1/en active Application Filing
- 2021-07-07 BR BR112023000323A patent/BR112023000323A2/pt unknown
- 2021-07-07 EP EP21740222.1A patent/EP4178612A1/en active Pending
- 2021-07-07 AR ARP210101904A patent/AR122899A1/es unknown
- 2021-07-07 TW TW110125037A patent/TW202207979A/zh unknown
-
2023
- 2023-01-31 CO CONC2023/0001072A patent/CO2023001072A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2023001072A2 (es) | 2023-06-20 |
KR20230049084A (ko) | 2023-04-12 |
TW202207979A (zh) | 2022-03-01 |
CA3184878A1 (en) | 2022-01-13 |
AU2021303789A1 (en) | 2023-02-16 |
WO2022009121A1 (en) | 2022-01-13 |
IL299735A (en) | 2023-03-01 |
GB202010425D0 (en) | 2020-08-19 |
MX2023000411A (es) | 2023-04-10 |
JP2023533772A (ja) | 2023-08-04 |
GB2596820A (en) | 2022-01-12 |
BR112023000323A2 (pt) | 2023-01-31 |
US20230256085A1 (en) | 2023-08-17 |
EP4178612A1 (en) | 2023-05-17 |
CN117957016A (zh) | 2024-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122899A1 (es) | Combinación de vacunas | |
AR121361A1 (es) | Vacuna | |
ECSP17077930A (es) | Métodos y kits para tratar la depresión | |
CO2019001379A2 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih . | |
BR112017001310A2 (pt) | coronavírus | |
CL2018002692A1 (es) | Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961) | |
CL2019003805A1 (es) | Composiciones inmunógenas de senecavirus a y métodos de éstas. | |
UY32457A (es) | Vacuna del virus del dengue inactivado | |
BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
CO2021006308A2 (es) | Proteínas f de prefusión del vrs estabilizadas | |
BR112014021065A2 (pt) | Inibidor de uma interação entre fosfatidilserina e um receptor tam, composição farmacêutica e uso de um inibidor | |
CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
BR112022016893A2 (pt) | Vacina contra a infecção do vírus da peste suína africana | |
CL2023000699A1 (es) | Tratamientos de angioedema | |
CL2018001946A1 (es) | Virus atenuados de bronquitis infecciosa. | |
BR112012015202A2 (pt) | "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes". | |
CL2007002710A1 (es) | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. | |
AR101814A1 (es) | Partícula de tipo virus flavivirus | |
CO2024006742A2 (es) | Compuestos terapéuticos para la infección por el virus del vih | |
UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
BR112018069100A2 (pt) | uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae | |
BR112015026243A2 (pt) | método de inibição viral | |
AR082278A1 (es) | Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (iii) | |
BR112020010202A8 (pt) | Cepa para vacina de influenza aviária h9 que diferencia animais infectados de vacinados, e método de preparação para a mesma |